For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

5177 products · Showing 4721–4740 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure

Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC50 of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity.

Aurora kinase inhibitor-11

Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells.

Aβ42 agonist-1

Tyrosinase-IN-17 (Compound 5b) is a lipophilic, skin-permeable, and non-cytotoxic Tyrosinase inhibitor (pIC50=4.99). Tyrosinase-IN-17 can be used for research on melanin-related diseases, such as melanoma, melanogenesis, etc.

Tyrosinase-IN-17
OxiperomideFeatured

Dual dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential

Oxiperomide

Anti-inflammatory agent 63 is an anti-inflammatory agent that shows optimal inhibitory activity (EC50 = 5.33±0.57 μM) against the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) in RAW264.7 cells.

Anti-inflammatory agent 63

Nurr1 agonist 7 (compound 110) is a Nurr1 agonist with an EC50 value of 0.12 μM.

Nurr1 agonist 7

Topoisomerase I inhibitor 9 (compound 3d) is a leishmanial topoisomerase IB inhibitor. Topoisomerase I inhibitor 9 has antileishmanial activity against L. donovani promastigotes, with the IC50 of 34.81μM.

Topoisomerase I inhibitor 9
WAY-309236Featured

WAY-309236 is an active molecule for the study of amyloid diseases and synucleinopathies.

WAY-309236
WAY-323756Featured

WAY-323756 is an active molecule for research into amyloid diseases and synucleinopathies.

WAY-323756
WAY-232897Featured

WAY-232897 is an active molecule for the study of amyloid diseases and synucleinopathies.

WAY-232897
TNKS-2-IN-2Featured

TNKS-2-IN-2 is a potent and selective inhibitor of TNKS2 with an IC50 of 22 nM.

TNKS-2-IN-2
PP5-IN-1Featured

PP5-IN-1 (Compound P053) is a competitive inhibitor of Serine/threonine protein phosphatase-5 (PP5) that binds to its catalytic domain and causes apoptosis in renal cancer.

PP5-IN-1
A3373Featured

A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis.

A3373

mAChR antagonist 1 (compound 4a) is a mAChR antagonist with Ki values of 255 nM, 121 nM, 158 nM, and 255 nM for M1, M3, M4, and M5 subtype, respectively.

mAChR antagonist 1
Cga-jk3Featured

CGA-JK3 is an ATP-competitive inhibitor of IKKβ-catalyzed kinase activity. CGA-JK3 inhibits IκBα phosphorylation in LPS (HY-D1056) - induced RAW 264.7 cells.

Cga-jk3

Sirtuin-1 inhibitor 1 (Compound 8) is an inhibitor of Sirtuin-1 that plays important roles in obesity-induced diabetes and aging-related diseases.

Sirtuin-1 inhibitor 1
Prmt5-in-c17Featured

Novel potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor

Prmt5-in-c17
P-2281Featured

Novel potent inhibitor of mTOR activity, significantly suppressing macroscopic and histologic abnormalities associated with chemically-induced murine ulcerative colitis.

P-2281
BRD2492Featured

BRD2492 is a highly potent, selective HDAC1/2 inhibitor (IC50=2/19 nM, respectively) that displays excellent selectivity versus HDAC3 (IC50=2.08 uM, ≥110-fold selectivity) and all other HDAC isoforms, increases caspase-3 activation..

BRD2492

Page 237 of 259 · Browse all 5177 products

Jump to a product page

Featured literature product: HX1 · DCL0028

HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.

Read full formulation and performance →